Uric acid and incident chronic kidney disease in dyslipidemic individuals

References

• Group KDIGOKCW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150
   Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. The Lancet 2005;366:2026-33
   PubMed Web of Science ®Google Scholar
• Kakafika A, Liamis G, Elisaf M, et al. Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 2001;17:230-1
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47
   PubMed Web of Science ®Google Scholar
• Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006;32:275-93, v–vi
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Cook S, et al. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007;115:2526-32
   PubMed Web of Science ®Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-93
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97
   PubMed Web of Science ®Google Scholar
• Kang D-H, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005;25:43-9
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90
   PubMed Web of Science ®Google Scholar
• Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-47
   PubMed Web of Science ®Google Scholar
• Yen CJ, Chiang CK, Ho LC, et al. Hyperuricemia associated with rapid renal function decline in elderly Taiwanese subjects. J Formos Med Assoc 2009;108:921-8
   PubMed Web of Science ®Google Scholar
• Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010;56:264-72
   PubMed Web of Science ®Google Scholar
• See LC, Kuo CF, Chuang FH, et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009;36:1691-8
   PubMed Web of Science ®Google Scholar
• Sturm G, Kollerits B, Neyer U, et al. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008;43:347-52
   PubMed Web of Science ®Google Scholar
• Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-50
   PubMed Web of Science ®Google Scholar
• Mok Y, Lee SJ, Kim MS, et al. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant 2012;27:1831-5
   PubMed Web of Science ®Google Scholar
• Chang HY, Lee PH, Lei CC, et al. Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: a prospective cohort study in taiwan. PLoS One 2013;8:e61450
   PubMed Web of Science ®Google Scholar
• Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005;16:791-9
   PubMed Web of Science ®Google Scholar
• Kawashima M, Wada K, Ohta H, et al. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol 2011;12:31
   PubMed Web of Science ®Google Scholar
• Ryoo JH, Choi JM, Oh CM, et al. The association between uric acid and chronic kidney disease in Korean men: a 4-year follow-up study. J Korean Med Sci 2013;28:855-60
   PubMed Web of Science ®Google Scholar
• Wang S, Shu Z, Tao Q, et al. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton) 2011;16:767-76
   PubMed Web of Science ®Google Scholar
• Kuwabara M, Bjornstad P, Hisatome I, et al. Elevated serum uric acid level predicts rapid decline in kidney function. Am J Nephrol 2017;45:330-7
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008;19:1204-11
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 2008;23:1265-73
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 2014;15:122
   PubMed Web of Science ®Google Scholar
• Sedaghat S, Hoorn EJ, van Rooij FJ, et al. Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One 2013;8:e76827
   PubMed Web of Science ®Google Scholar
• Hughes K, Flynn T, de Zoysa J, et al. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int 2014;85:344-51
   PubMed Web of Science ®Google Scholar
• Testa A, Mallamaci F, Spoto B, et al. Association of a polymorphism in a gene encoding a urate transporter with CKD progression. Clin J Am Soc Nephrol 2014;9:1059-65
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93
   PubMed Web of Science ®Google Scholar
• Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011;6:1887-94
   PubMed Web of Science ®Google Scholar
• Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011;22:1382-9
   PubMed Web of Science ®Google Scholar
• Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011;58:2-7
   PubMed Web of Science ®Google Scholar
• Saito J, Matsuzawa Y, Ito H, et al. The alkalizer citrate reduces serum uric acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. Endocr Res 2010;35:145-54
   PubMed Web of Science ®Google Scholar
• Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol 2016;10:306-13
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, et al. High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. Atherosclerosis 2016;247:58-63
   PubMed Web of Science ®Google Scholar
• Barkas F, Milionis H, Kostapanos MS, et al. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin 2015;31:221-8
   PubMed Web of Science ®Google Scholar
• Barkas F, Liberopoulos E, Klouras E, et al. Attainment of multifactorial treatment targets among the elderly in a lipid clinic. J Geriatr Cardiol 2015;12:239-45
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219
   PubMed Web of Science ®Google Scholar
• Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest 1950;29:496-507
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. The Lancet 2013;382:260-72
   PubMed Web of Science ®Google Scholar
• Borgi L, McMullan C, Wohlhueter A, et al. Effect of uric acid-lowering agents on endothelial function: a randomized, double-blind, placebo-controlled trial. Hypertension 2017;69:243-8
   PubMed Web of Science ®Google Scholar
• Jalal DI, Decker E, Perrenoud L, et al. Vascular function and uric acid-lowering in stage 3 CKD. J Am Soc Nephrol 2017;28:943-52
   PubMed Web of Science ®Google Scholar
• Tonna SJ. Invited commentary: defining incident chronic kidney disease in epidemiologic study settings. Am J Epidemiol 2009;170:425-7
   PubMed Web of Science ®Google Scholar
• Madero M, Sarnak MJ. Creatinine-based formulae for estimating glomerular filtration rate: is it time to change to chronic kidney disease epidemiology collaboration equation? Curr Opin Nephrol Hypertens 2011;20:622-30
   PubMed Web of Science ®Google Scholar